drugset / Trial / NCT01128855
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is investigate the pharmacokinetics, safety and tolerability of single subcutaneous administration of GSK2402968 in non-ambulant boys with Duchenne muscular dystrophy
Timeline
- Start
- 2010-07-12
- Primary completion
- 2011-10-25
- Completion
- 2011-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Drisapersen | Antisense oligonucleotide | 3 mg/kg | Subcutaneous |
| Subject | Drisapersen | Antisense oligonucleotide | 6 mg/kg | Subcutaneous |
| Subject | Drisapersen | Antisense oligonucleotide | 9 mg/kg | Subcutaneous |
| Subject | Drisapersen | Antisense oligonucleotide | 12 mg/kg | Subcutaneous |